Related references
Note: Only part of the references are listed.Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma
Dominic P. Decker et al.
LEUKEMIA & LYMPHOMA (2020)
Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy
Wilhelm Woessmann et al.
BLOOD (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Lasse H. Jakobsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
Mark Roschewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy
Adam S. Zayac et al.
LEUKEMIA & LYMPHOMA (2020)
Approach to the Diagnosis and Treatment of Adult Burkitt's Lymphoma
Kieron Dunleavy
JOURNAL OF ONCOLOGY PRACTICE (2018)
DA-EPOCH-R for Adult Burkitt's Lymphoma: Pros and Cons
Juan Pablo Alderuccio et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens
L. E. M. Oosten et al.
ANNALS OF HEMATOLOGY (2018)
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma
Nicholas J. Short et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag et al.
LANCET (2016)
AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
Ariela Noy et al.
BLOOD (2015)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Dieter Hoelzer et al.
BLOOD (2014)
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10002
David A. Rizzieri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group
T. Wasterlid et al.
ANNALS OF ONCOLOGY (2013)
Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research
Leena V. Maramattom et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Low-Intensity Therapy in Adults with Burkitt's Lymphoma
Kieron Dunleavy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma
Gaetano Corazzelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Graham M. Mead et al.
BLOOD (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
V. Boehme et al.
ANNALS OF ONCOLOGY (2007)
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
DA Thomas et al.
CANCER (2006)
Burkitt lymphoma in adults:: a prospective study of 72 patients treated with an adapted pediatric LMB protocol
M Diviné et al.
ANNALS OF ONCOLOGY (2005)
Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity
A Lacasce et al.
LEUKEMIA & LYMPHOMA (2004)
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study
GM Mead et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
